全文获取类型
收费全文 | 6468篇 |
免费 | 360篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 253篇 |
妇产科学 | 160篇 |
基础医学 | 1030篇 |
口腔科学 | 88篇 |
临床医学 | 417篇 |
内科学 | 1188篇 |
皮肤病学 | 193篇 |
神经病学 | 636篇 |
特种医学 | 261篇 |
外国民族医学 | 5篇 |
外科学 | 883篇 |
综合类 | 99篇 |
预防医学 | 294篇 |
眼科学 | 185篇 |
药学 | 447篇 |
中国医学 | 1篇 |
肿瘤学 | 680篇 |
出版年
2023年 | 38篇 |
2022年 | 78篇 |
2021年 | 92篇 |
2020年 | 70篇 |
2019年 | 80篇 |
2018年 | 106篇 |
2017年 | 81篇 |
2016年 | 120篇 |
2015年 | 143篇 |
2014年 | 174篇 |
2013年 | 218篇 |
2012年 | 277篇 |
2011年 | 311篇 |
2010年 | 175篇 |
2009年 | 201篇 |
2008年 | 305篇 |
2007年 | 264篇 |
2006年 | 299篇 |
2005年 | 293篇 |
2004年 | 254篇 |
2003年 | 258篇 |
2002年 | 221篇 |
2001年 | 238篇 |
2000年 | 216篇 |
1999年 | 195篇 |
1998年 | 121篇 |
1997年 | 99篇 |
1996年 | 97篇 |
1995年 | 49篇 |
1994年 | 67篇 |
1993年 | 58篇 |
1992年 | 107篇 |
1991年 | 97篇 |
1990年 | 86篇 |
1989年 | 86篇 |
1988年 | 114篇 |
1987年 | 91篇 |
1986年 | 79篇 |
1985年 | 73篇 |
1984年 | 52篇 |
1983年 | 43篇 |
1982年 | 35篇 |
1981年 | 32篇 |
1979年 | 52篇 |
1975年 | 34篇 |
1974年 | 41篇 |
1973年 | 36篇 |
1972年 | 33篇 |
1971年 | 32篇 |
1966年 | 46篇 |
排序方式: 共有6859条查询结果,搜索用时 15 毫秒
1.
U. Bolm-Audorff S. Brandenburg T. Brüning H. Dupuis R. Ellegast G. Elsner K. Franz H. Grasshoff V. Grosser L. Hanisch B. Hartmann E. Hartung K. G. Hering G. Heuchert M. Jäger J. Krämer Dr. A. Kranig E. Ludolph A. Luttmann A. Nienhaus W. Pieper K.-D. Pöhl T. Remé D. Riede G. Rompe K. Schäfer S. Schilling E. Schmitt F. Schröter A. Seidler M. Spallek M. Weber 《Trauma und Berufskrankheit》2005,7(3):211-252
Occupational diseases Nos. 2108 and 2110 correspond to intervertebral disc-related diseases of the lumbar spine from many years of carrying or lifting heavy loads, occupations in extreme postures of full flexion or oscillation of the whole body when seated, and which compel the cessation of all activities which are or could be the cause for the origin, exacerbation or recurrence of the disease. These occupational diseases came into force at the start of 1993, but there have been considerable problems in their implementation. The present Part I of the contribution is the result of the work of an interdisciplinary study group and contains medical criteria for the assessment of possibly strain-related clinical characteristics and the evaluation of other possible causes. Part II is to be published in Volume 4/2005 and will deal with questions related to forced cessation and to the assessment of the loss of earning ability. Agreement was reached in many areas related to the assessment of occupational claims. This should allow for evidence-based decision making in the future for the occupational diseases Nos. 2108 and 2110. 相似文献
2.
C. Bokemeyer K. Oechsle J.-T. Hartmann 《European journal of clinical investigation》2005,35(S3):26-31
3.
4.
Sandra Urdaneta Hartmann Brian Wigdahl Elizabeth B Neely Cheston M Berlin Cara-Lynne Schengrund Hung-Mo Lin Mary K Howett 《Journal of human lactation》2006,22(1):61-74
Reduction of transmission of human immunodeficiency virus type 1 (HIV-1) through human milk is needed. Alkyl sulfates such as sodium dodecyl sulfate (SDS) are microbicidal against HIV-1 at low concentrations, have little to no toxicity, and are inexpensive. The authors have reported that treatment of HIV-1-infected human milk with < or = 1% (10 mg/mL) SDS for 10 minutes inactivates cell-free and cell-associated virus. The SDS can be removed with a commercially available resin after treatment without recovery of viral infectivity. In this article, the authors report results of selective biochemical analyses (ie, protein, immunoglobulins, lipids, cells, and electrolytes) of human milk subjected to SDS treatment and removal. The SDS treatment or removal had no significant effects on the milk components studied. Therefore, the use of alkyl sulfate microbicides to treat milk from HIV-1-positive women may be a simple, practical, and nutritionally sound way to prevent or reduce transmission of HIV-1 while still feeding with mother's own milk. 相似文献
5.
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients 总被引:1,自引:0,他引:1
A. Åsberg A. Humar H. Rollag A. G. Jardine H. Mouas M. D. Pescovitz D. Sgarabotto M. Tuncer I. L. Noronha A. Hartmann 《American journal of transplantation》2007,7(9):2106-2113
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized, international trial, recipients with cytomegalovirus disease were treated with either 900 mg oral valganciclovir or 5 mg/kg i.v. ganciclovir twice daily for 21 days, followed by 900 mg daily valganciclovir for 28 days. A total of 321 patients were evaluated (valganciclovir [n = 164]; i.v. ganciclovir [n = 157]). The success rate of viremia eradication at Day 21 was 45.1% for valganciclovir and 48.4% for ganciclovir (95% CI -14.0% to +8.0%), and at Day 49; 67.1% and 70.1%, respectively (p = NS). Treatment success, as assessed by investigators, was 77.4% versus 80.3% at Day 21 and 85.4% versus 84.1% at Day 49 (p = NS). Baseline viral loads were not different between groups and decreased exponentially with similar half-lives and median time to eradication (21 vs. 19 days, p = 0.076). Side-effects and discontinuations of assigned treatment (18 of 321 patients) were comparable. Oral valganciclovir shows comparable safety and is not inferior to i.v. ganciclovir for treatment of cytomegalovirus disease in organ transplant recipients and provides a simpler treatment strategy, but care should be taken in extrapolating to organ transplant recipients not properly represented in the present study. 相似文献
6.
U. Bolm-Audorff S. Brandenburg T. Brüning H. Dupuis R. Ellegast G. Elsner K. Franz H. Grasshoff V. Grosser L. Hanisch B. Hartmann E. Hartung† K. G. Hering G. Heuchert M. Jäger J. Krämer Dr. A. Kranig E. Ludolph A. Luttmann A. Nienhaus W. Pieper K. D. Pöhl T. Remé D. Riede G. Rompe K. Schäfer S. Schilling E. Schmitt F. Schröter A. Seidler M. Spallek M. Weber 《Trauma und Berufskrankheit》2005,7(4):320-332
The first part of this serial paper dealt with the medical criteria used in evaluation of the clinical picture caused by physical stress and the evaluation of other candidate causes and was published in issue no. 3/2005 (pp. 711–752) of Trauma and Berufskrankheit. This follow-up paper (II) presents criteria to be used in the evaluation of whether it is necessary to give up the occupations putting the spine at risk and in estimation of the degree of disability. 相似文献
7.
Gregory J. Pomper Rita A. Joseph Erica L. Hartmann Michael S. Rohr Patricia L. Adams Robert J. Stratta 《American journal of transplantation》2005,5(10):2586-2589
Massive immune hemolysis due to passenger lymphocyte-derived anti-D has not been reported in renal transplantation. A 50-year-old (B-positive) male received a dual deceased-donor kidney transplant (B-negative) for diabetic renal failure. Two weeks post-transplant, the patient developed severe hemolytic anemia. The donor anti-D titer was 1:8. The recipient anti-D titer (zero pre-transplant) increased from 1:4 to 1:16 over 4 days. Rapid hemolysis caused severe anemia, minimum Hb = 4.2 g/dL, while selectively lysing the patient's autologous red cells during this time. The hemolytic anemia did not impair the allografts and subsided without monoclonal B-cell pharmacotherapy or apheresis. The anti-D titer decreased to barely detectable levels at four months and had cleared when checked 2 years post-transplant. Transfusion support subsided after two months. If complications of anemia can be avoided, the deleterious effects of hemolysis may be well tolerated by renal allografts using antigen negative transfusion alone. 相似文献
8.
9.
Ladenstein Ruth; Pearce Rachel; Hartmann Olivier; Patte Catherine; Goldstone Tony; Philip Thierry 《Blood》1997,90(8):2921-2930
10.
Rolf W. Hartmann Martin Frotscher Dorothea Ledergerber Gerald A. Wchter Gertrud L. Grün Tom F. Sergejew 《Archiv der Pharmazie》1996,329(5):251-261
In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralones, tetralins, and dihydronaphthalenes bearing a OCH3 substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituent in 2-position were synthesized with and without C1-spacer between the rings (compounds 2 – 26 ). The compounds were tested in vitro for inhibition of the three target enzymes P450 arom (human placental microsomes), P450 17 (rat testicular microsomes), and P450 TxA2 (citrated human whole blood). To examine selectivity, some compounds were further tested in vitro for inhibition of P450 18 (bovine adrenal mitochondria), P450 see (bovine adrenal mitochondria) and corticoid formation (aldosterone, corticosterone; ACTH stimulated rat adrenal tissue). In vivo, selected compounds were examined in Sprague Dawley rats regarding P450 TxA2 inhibition, reduction of plasma testosterone concentration, antiuterotrophic activity (inhibition of the uterotrophic activity of androstenedione), reduction of plasma estradiol concentration (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compounds, which represent a novelty in the field of azole inhibitors of steroidogenic P450 enzymes, strong inhibitors of P450 arom and/or P450 17 were found: 7-OCH3-2-(imidazol-4-ylmethylene)-1-tetralone ( 4 ) and 7-OCH3-2-(imidazol-4-ylmethyl)-tetralin ( 12 ) are among the most potent inhibitors of P450 arom in vitro known so far. Compound 4 is a selective inhibitor, whereas 12 shows in addition strong inhibition of P450 17. In contrast to 12 , the 6-OCH3 derivative (compound 11 ) is a selective inhibitor of P450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compounds show a marked inhibition of P450 TxA2: 2-(imidazol-1-ylmethyl)-1-tetralone ( 13 ) is a selective inhibitor of P450 TxA2, whereas 7-OCH3-2-(imidazol-1-ylmethyl)-tetralin ( 17 ) as well as 2-(imidazol-1-ylmethyl)-tetralin ( 16 ) and 7-OCH3-2-imidazol-1-yl-3,4-dihydronaphthalene ( 25 ) additionally show strong inhibition of P450 arom and P450 17. Regarding the other steroidogenic P450 enzymes as well as corticosterone formation, the compounds show only little inhibitory activity. Aldosterone formation, however, is inhibited at low concentrations. Nevertheless, 4 and 12 are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P450 arom fadrozole. The compounds show activity in the aforementioned in vivo tests. 相似文献